Abstract
The development of a suitable oral solid dosage form of cimetidine has been examined from the standpoint of equal bioavailability for different formulations. The in vitro characteristics of one capsule and four tablet formulations were determined. From the areas under the blood level/time curves in healthy volunteers, equal bioavailability was shown between the capsule, the original tablet formulation chosen for early clinical trials and the final tablet formulation used for commercial production.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
